Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis-Reference-Cited by-同舟云学术

Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis

Published:2022-12-12 Issue:1 Volume:80 Page:221-230
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Sesti F.,Puliani G.,Feola T.,Campolo F.,Sciarra F.,Hasenmajer V.,Lenzi A.,Faggiano A.,Isidori A. M.,Venneri M. A.,Giannetta E.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-022-03257-8.pdf

Reference47 articles.

1. M. Cives, J.R. Strosberg, Gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin. 68(6), 471–487 (2018)

2. M. Bartolomei, A. Berruti, M. Falconi, N. Fazio, D. Ferone, S. Lastoria, et al. Clinical management of neuroendocrine neoplasms in clinical practice: a formal consensus exercise. Cancers. 14(10), 2501 (2022).

3. T.F. Gajewski, H. Schreiber, Y.X. Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14(10), 1014–1022 (2013)

4. D.C. Hinshaw, L.A. Shevde, The tumor microenvironment innately modulates cancer progression. Cancer Res. 79(18), 4557–66. (2019)

5. K. Imai, S. Matsuyama, S. Miyake, K. Suga, K. Nakachi, Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356(9244), 1795–1799 (2000)

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia;Cancers;2023-07-12

2. Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues;Biomedicines;2023-03-10